|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2000033103 |
|
最近更新日期: Date of Last Refreshed on: |
2020-05-20 22:13:54 |
|
注册时间: Date of Registration: |
1990-01-01 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
待编辑(三)抗阻训练对胃肠肿瘤病人化疗后副作用和生活质量效果的临床研究 |
|
Public title: |
Effects of resistance exercise on adverse events, physical function, and quality of life in gastrointestinal cancer patients undergoing chemotherapy |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
抗阻训练对胃肠肿瘤病人化疗后副作用和生活质量效果的临床研究 |
|
Scientific title: |
Effects of resistance exercise on adverse events, physical function, and quality of life in gastrointestinal cancer patients undergoing chemotherapy |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
吴春梅 |
研究负责人: |
吴春梅 |
|
Applicant: |
Wu Chunmei |
Study leader: |
Wu Chunmei |
|
申请注册联系人电话: Applicant telephone: |
13505992351 |
研究负责人电话: Study leader's telephone: |
13505992351 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
wcm770928@163.com |
研究负责人电子邮件: Study leader's E-mail: |
wcm770928@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
福建省医科大学附属泉州市第一医院,362000 |
研究负责人通讯地址: |
福建省医科大学附属泉州市第一医院,362000 |
|
Applicant address: |
Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China, 362000 |
Study leader's address: |
Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China, 362000 |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
福建省医科大学附属泉州市第一医院 |
||
|
Applicant's institution: |
Quanzhou First Hospital Affiliated to Fujian Medical University |
||
|
研究负责人所在单位: |
|
||
|
Affiliation of the Leader: |
|
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2019WCM |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
福建省医科大学附属泉州市第一医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethical Committee of Quanzhou First Hospital Affiliated to Fujian Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2019-12-15 00:00:00 |
||
|
伦理委员会联系人: |
福建省医科大学附属泉州市第一医院伦理委员会 |
||
|
Contact Name of the ethic committee: |
Ethical Committee of Quanzhou First Hospital Affiliated to Fujian Medical University |
||
|
伦理委员会联系地址: |
福建省医科大学附属泉州市第一医院伦理委员会 |
||
|
Contact Address of the ethic committee: |
Ethical Committee of Quanzhou First Hospital Affiliated to Fujian Medical University |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
福建省医科大学附属泉州市第一医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Quanzhou First Hospital Affiliated to Fujian Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
福建省医科大学附属泉州市第一医院,362000 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China, 362000 |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
None |
||||||||||||||||||||||
|
Target disease: |
Gastrointestinal cancer |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
I期临床试验 | ||||||||||||||||||||||
|
Study phase: |
1 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
抗阻训练对胃肠肿瘤病人化疗后副作用和生活质量效果的临床研究 |
||||||||||||||||||||||
|
Objectives of Study: |
Effects of resistance exercise on adverse events, physical function, and quality of life in gastrointestinal cancer patients undergoing chemotherapy |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
年龄 ≥ 18岁, 预期寿命 ≥ 6个月, 体脂率(BMI) ≥18 kg/m2, 且有能力和意愿完成研究项目 |
||||||||||||||||||||||
|
Inclusion criteria |
age ≥ 18 years, life expectancy ≥6 months, body mass index (BMI) ≥18 kg/m2, and capacity and willingness to execute the study protocol |
||||||||||||||||||||||
|
排除标准: |
在此研究前参与过其他有氧或抗阻训练, 或有其它影响进行抗阻训练的严重疾病 |
||||||||||||||||||||||
|
Exclusion criteria: |
participating other aerobic or resistance training before this research, having contraindications for resistance training, and having other concurrent malignant diseases |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2019-12-15 00:00:00至 To 2021-12-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2020-06-01 00:00:00 至 To 2022-06-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
Excel随机分组 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Excel randomization group allocation |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
www.medresman.org |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
www.medresman.org |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
www.medresman.org |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
www.medresman.org |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |